ClinicalTrials.gg
CompletedNCT05825911EDAM-CADUpdated Oct 19, 2026

Evaluation of Diagnostic Accuracy of MCG(Magnetocardiography) Scan in Suspected Coronary Artery Disease

An observational study in Coronary Artery Disease, sponsored by AMCG. Completed at 2 sites in South Korea. Open to participants aged 19 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by AMCG · Observational

How we know

Updated Oct 19, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 361 studies in Coronary Artery Disease with a site in Korea, Republic of — 81 open to participants now, 103 under way, 2 of them phase 3. Coronary Artery Disease · Korea, Republic of.

Enrollment
98th of 152
600 · median 1,113
Started
2024
with 12 others
Observational
153 of 361
40 open now
Registered
298th of 361
by date

Among the 361 studies in Coronary Artery Disease with a site in Korea, Republic of, this one is the 98th largest by enrollment of the 152 observational ones that give a count, is one of 13 that started in 2024, is one of 153 observational ones, and was the 298th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

81 of the 361 studies in Coronary Artery Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Coronary Artery Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This multicenter clinical trial is designed to evaluate the diagnostic accuracy of MCG scan in detecting significant CAD compared to the reference standard CAG.

Read the detailed description

This is multicenter, prospective, observational trial to evaluate the diagnostic accuracy of magnetocardiography(MCG) scan in detecting significant coronary artery disease(CAD) compared to the reference standard coronary arteriography(CAG). Chest pain patients scheduled for CAG will be offered to enroll in this clinical trial and provide informed consent to undergo with a rest/stress MCG scan prior to CAG. This MCG scan with a new 96 channel superconducting quantum interference device(SQUID) system is radiation-free, contactless and takes less than ten minutes to complete. Multiple studies have shown that the diagnostic accuracy of stress MCG scan is quite high in identifying patients with symptomatic CAD. Results will be interpreted and compared to the results of cardiac SPECT stress test, if available, and CAG. Participants will be followed up to 30 days via phone call or chart review. 30 day major adverse cardiac event(MACE) will be recorded and correlated with initial MCG scan results.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Magnetocardiography scan
  • Coronary Artery Disease
04

Who can participate

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  1. MAIN STUDY: This is an adult population at varying risk for CAD who will present at multicenter for cardiovascular screening with CAG.
  2. SUB-STUDY: This is an normal adult population with age-, and sex-matched control group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 19 years of age at the time of enrollment
  • Patient presenting for CAG
  • Consents to having an MCG scan study

Exclusion criteria

Exclusion Criteria:

  • Patients unable to fit into MCG scan device
  • Patients with implanted cardiac pacemakers/defibrillators
  • Atrial fibrillation with rapid ventricular response
  • Patients with other sustained or incessant arrhythmias
  • Presence clinical suspicious of any acute coronary syndrome
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (actual)
Target follow-up
1 Month
Patient registry
Yes

Interventions

  • Diagnostic testRest/Stress MCG scan

    All patients enrolled and receiving standard screening tests for CAD will undergo rest/stress MCG scan before CAG.

  • Diagnostic testRest MCG scan

    This is an normal adult population with age-, and sex-matched control group. All participants enrolled will undergo rest MCG scan.

06

What researchers measure

Primary outcomes

  1. Sensitivity and specificity of MCG scan

    Compare the diagnostic accuracy of stress MCG scan in detecting significant CAD compared to the current standard reference coronary angiogram(CAG) with statistical analysis including sensitivity, specificity.

    Time frame: 1 day

Secondary outcomes

  1. Positive predictive value(PPV), Negative predictive value(NPV), and diagnostic accuracy of MCG scan

    Comparison with CAG will be performed for those having stress MCG scan test with statistical analysis including PPV, NPV, and diagnostic accuracy.

    Time frame: 1 day

Other outcomes

  1. Major adverse cardiac event after 30 days of CAG

    The frequency and percentage of MACE collected 30 days after the end of the CAG and the types of events are presented. At this time, major adverse cardiovascular events (MACEs) to be collected include death due to cardiovascular disease (CV Death), myocardial infarction (Nonfatal MI), and ischemic cardiovascular events (Ischemic CV events).

    Time frame: 1 month

  2. Comparison of MCG scan with cardiac SPECT test

    Comparison with cardiac SPECT test will be performed with statistical analysis including sensitivity and specificity.

    Time frame: 1 day

  3. Comparison of sensitivity and specificity between stress MCG scan and stress ECG test

    Comparison of sensitivity and specificity between stress MCG scan and stress ECG test

    Time frame: 1 day

07

Study locations

2 sites
  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital
    Seoul, Eunpyeong-gu 03312, South Korea
  • Gachon University Gil Medical Center
    Incheon, Namdong-gu 21565, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Dec 2025, 18 months.

Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's 18 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

Completion moved once since we started tracking on Sep 25, 2026: Jan 2026 → Dec 2025, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2023
First posted
Apr 24, 2023
StartActual
Jun 24, 2024
Primary completionActual
Dec 30, 2025
CompletionActual
Dec 30, 2025was Jan 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 19, 2026
Study completion
Jan 2026→Dec 30, 2025 (actual)
Oct 19, 2026
Enrollment
908 (estimated)→600 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Recruiting→Completed
    Study completion Jan 2026→Dec 30, 2025 (now actual)
    Enrollment 908 (estimated)→600 (actual)
    + 4 other changes: index terms, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05825911
Lead sponsor
AMCG
Responsible party
Sponsor
First posted
Apr 24, 2023
Start date
Jun 24, 2024
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Oct 19, 2026

Study contacts

Hoseong Lee Deputy general manager
study director · AMCG

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion